Clinical trial

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

NCT00700336

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-05-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2008-05-01Date precision: month

Registry last updated2021-07-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Malignant Pleural Mesotheliomaunresolved

Solid Tumorsunresolved

Interventions

pemetrexed, cisplatin and CBP501DRUG

pemetrexed and cisplatinDRUG

pemetrexed, cisplatin and CBP501, dose findingDRUG

Sponsors & collaborators

CanBas Co. Ltd.lead sponsor

Mapped research locations

New YorkNew York, United States1 ChicagoIllinois, United States1 San AntonioTexas, United States1 ClevelandOhio, United States1 DetroitMichigan, United States1 Salt Lake CityUtah, United States1 Las VegasNevada, United States1 TucsonArizona, United States1 AlbuquerqueNew Mexico, United States1 ScottsdaleArizona, United States1 DuarteCalifornia, United States1 HersheyPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00700336 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.